The present invention relates to compounds that are pharmaceutically active and methods of preparation thereof. The compounds of the invention are 7-hydroxy-cannabidol-C4 (7-OH-CBD-C4) and 7-carboxy-cannabidiol-C4 (7-COOH-CBD-C4). The compounds of the invention are related to cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the compounds of the invention.
C07C 39/23 - Composés comportant au moins un groupe hydroxyle ou O-métal lié à un atome de carbone d'un cycle aromatique à six chaînons polycycliques contenant des cycles aromatiques à six chaînons et d'autres cycles avec une insaturation autre que celle des cycles aromatiques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
31 - Produits agricoles; animaux vivants
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical and veterinary preparations and substances;
pharmaceutical preparations and substances for the treatment
of epilepsy, paediatric epilepsy, oncology, psychiatric
disorders, type II diabetes, inflammation, cancer pain, MS
spasticity and neonatal hypoxic-ischemic encephalopathy;
herbs for medicinal purposes; medicinal herbs; medicinal
oils; medicinal infusions; pure extracts of medicinal plants
and herbs; foodstuffs for medicinal purposes; herb teas for
medicinal purposes. Agricultural and horticultural products; seeds; seedlings;
flowers; plants; plant residues (raw materials); animal food
containing plant extracts; fresh herbs; animal foodstuffs;
beverages for pets. Custom manufacturing services in relation to chemicals and
pharmaceuticals; custom manufacture of chemicals and
pharmaceuticals; information, advisory and consultancy
services in relation to all of the aforesaid services. Educational services; instruction and training services;
education services relating to medicine; organising and
conducting seminars and conventions in the field of
medicine; information, advisory and consultancy services in
relation to all of the aforesaid services. Scientific and technological services and research and
design relating thereto; chemical analysis; chemical
research; scientific and technological research and
development; research and development on the subject of
pharmaceuticals; consultancy relating to pharmaceutical
research and development; conducting clinical trials in the
field of pharmaceuticals; providing medical and scientific
research information in the field of pharmaceuticals and
clinical trials; information, advisory and consultancy
services in relation to all of the aforesaid services. Medical services, veterinary services, medical analysis
services; pharmaceutical services; pharmaceutical advisory
services; provision of pharmaceutical information; providing
consultancy and information in the field of medicine;
horticultural services; information, advisory and
consultancy services in relation to all of the aforesaid
services.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
31 - Produits agricoles; animaux vivants
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical, medical and veterinary preparations and
substances; pharmaceutical preparations and substances for
the treatment of neurological conditions, disorders and
diseases; pharmaceutical preparations and substances for the
treatment of epilepsy; pharmaceutical preparations and
substances for the treatment of pediatric epilepsy;
pharmaceutical preparations and substances for the treatment
of convulsions, seizures, Dravet syndrome, Lennox-Gastaut
syndrome, tuberous sclerosis complex, intractable childhood
epilepsy with generalized tonic-clonic seizures, generalized
epilepsy with febrile seizures plus, Doose syndrome and
chromosome disorders; medications for the treatment of
multiple sclerosis, pain associated with cancer,
neuropathies and rheumatoid arthritis; medicines for the
treatment of symptoms including pain, muscle spasticity and
spasms, bladder problems and sleep disorders; medications
for the treatment of conditions to which neuropathic pain is
associated, including multiple sclerosis, cancer, spinal
cord injury, physical trauma and peripheral neuropathy
resulting from diabetes; medicines for the treatment of
anorexia-cachexia, the result of cancer or AIDS, and nausea,
and secondary vomiting due to chemotherapy treatments; herbs
for medicinal purposes; medicinal herbs; medicinal oils;
medicinal infusions; medicinal infusions for the treatment
of epilepsy, convulsions and seizures; pure extracts of
medicinal plants and herbs; foodstuffs for medicinal
purposes; dietary supplements for humans and animals;
dietetic food and substances adapted for medical or
veterinary use; food for babies; herb teas for medicinal
purposes. Agricultural and horticultural products; seeds; seedlings;
flowers; plants; plant residues (raw materials); animal food
containing plant extracts; fresh herbs; animal foodstuffs;
beverages for pets. Manufacturing services in relation to chemicals and
pharmaceuticals; custom manufacture of chemicals and
pharmaceuticals; information, advisory and consultancy
services in relation to all of the aforesaid services. Educational services; instruction and training services;
education services relating to medicine; organising and
conducting seminars and conventions in the field of
medicine; information, advisory and consultancy services in
relation to all of the aforesaid services. Scientific and technological services and research and
design relating thereto; chemical analysis; chemical
research; scientific and technological research and
development; research and development on the subject of
pharmaceuticals; consultancy relating to pharmaceutical
research and development; conducting clinical trials in the
field of pharmaceuticals; providing medical and scientific
research information in the field of pharmaceuticals and
clinical trials; information, advisory and consultancy
services in relation to all of the aforesaid services. Medical services, veterinary services, medical analysis
services; pharmaceutical services; pharmaceutical advisory
services; provision of pharmaceutical information; providing
news and information in the field of medicine; horticultural
services; information, advisory and consultancy services in
relation to all of the aforesaid services.
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Manufacturing services in relation to chemicals and
pharmaceuticals; custom manufacture of chemicals and
pharmaceuticals; information, advisory and consultancy
services in relation to all of the aforesaid services. Educational services; instruction and training services;
education services relating to medicine; organising and
conducting seminars and conventions in the field of
medicine; information, advisory and consultancy services in
relation to all of the aforesaid services. Scientific and technological services and research and
design relating thereto; chemical analysis; chemical
research; scientific and technological research and
development; research and development on the subject of
pharmaceuticals; consultancy relating to pharmaceutical
research and development; conducting clinical trials in the
field of pharmaceuticals; providing medical and scientific
research information in the field of pharmaceuticals and
clinical trials; information, advisory and consultancy
services in relation to all of the aforesaid services. Medical services, veterinary services, medical analysis
services; pharmaceutical services; pharmaceutical advisory
services; provision of pharmaceutical information; providing
news and information in the field of medicine; horticultural
services; information, advisory and consultancy services in
relation to all of the aforesaid services.
5.
CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS
The invention relates to the use of one or more cannabinoids, particularly THC and/or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM). The non-cannabinoid chemotherapeutic agent may be a selective estrogen receptor modulator or an alkylating agent.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/4535 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p. ex. pizotifène
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Agricultural and horticultural products; seeds; flowers;
plants. Manufacturing services in relation to chemicals and
pharmaceuticals (term considered too vague by the
International Bureau - rule 13 (2) (b) of the Regulations);
custom manufacture of chemicals and pharmaceuticals;
information, advisory and consultancy services in relation
to all of the aforesaid services. Education; provision of training; instruction services;
organising and conducting conferences, seminars, exhibitions
and workshops; provision of on-line electronic publications;
publication of texts; publication of scientific texts. Scientific and technological services and research and
design relating thereto; chemical analysis; chemical
research; scientific and technological research and
development; research and development on the subject of
pharmaceuticals; consultancy relating to pharmaceutical
research and development; conducting clinical trials in the
field of pharmaceuticals; providing medical and scientific
research information in the field of pharmaceuticals and
clinical trials; information, advisory and consultancy
services in relation to all of the aforesaid services. Medical services; veterinary services; medical analysis
services; medical and veterinary information provided
on-line from a computer database or the Internet;
horticultural services; provision of horticultural
information.
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Agricultural and horticultural products; seeds; flowers;
plants. Manufacturing services in relation to chemicals and
pharmaceuticals (term considered too vague by the
International Bureau - rule 13 (2) (b) of the Regulations);
custom manufacture of chemicals and pharmaceuticals;
information, advisory and consultancy services in relation
to all of the aforesaid services. Education; provision of training; instruction services;
organising and conducting conferences, seminars, exhibitions
and workshops; provision of on-line electronic publications;
publication of texts; publication of scientific texts. Scientific and technological services and research and
design relating thereto; chemical analysis; chemical
research; scientific and technological research and
development; research and development on the subject of
pharmaceuticals; consultancy relating to pharmaceutical
research and development; conducting clinical trials in the
field of pharmaceuticals; providing medical and scientific
research information in the field of pharmaceuticals and
clinical trials; information, advisory and consultancy
services in relation to all of the aforesaid services. Medical services; veterinary services; medical analysis
services; medical and veterinary information provided
on-line from a computer database or the Internet;
horticultural services; provision of horticultural
information.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations; herbs for
medicinal purposes; medicinal herbs; medicinal oils;
medicinal infusions; pure extracts of medicinal plants and
herbs; foodstuffs for medicinal purposes; herb teas for
medicinal purposes.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations and substances;
pharmaceutical preparations and substances for the treatment
of epilepsy, paediatric epilepsy, oncology, psychiatric
disorders, type II diabetes, inflammation, cancer pain, MS
spasticity and neonatal hypoxic-ischemic encephalopathy;
herbs for medicinal purposes; medicinal herbs; medicinal
oils; medicinal infusions; pure extracts of medicinal plants
and herbs; foodstuffs for medicinal purposes; herb teas for
medicinal purposes.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical and veterinary preparations and substances for pain management; pharmaceutical preparations and substances for the treatment of epilepsy, paediatric epilepsy, oncology, psychiatric disorders, such as mood disorders and schizophrenia, type II diabetes, inflammation, cancer pain, multiple sclerosis spasticity and neonatal hypoxic-ischemic encephalopathy; medicinal herbs for the treatment of neurological conditions and diseases, namely treatment of epilepsy, paediatric epilepsy, oncology, psychiatric disorders, such as mood disorders and schizophrenia, type II diabetes, inflammation, cancer pain, multiple sclerosis spasticity and neonatal hypoxic-ischemic encephalopathy; medicinal oils for the treatment of neurological conditions and diseases, namely treatment of epilepsy, paediatric epilepsy, oncology, psychiatric disorders, such as mood disorders and schizophrenia, type II diabetes, inflammation, cancer pain, multiple sclerosis spasticity and neonatal hypoxic-ischemic encephalopathy; medicinal infusions for the treatment of neurological conditions and diseases, namely treatment of epilepsy, paediatric epilepsy, oncology, psychiatric disorders, such as mood disorders and schizophrenia, type II diabetes, inflammation, cancer pain, multiple sclerosis spasticity and neonatal hypoxic-ischemic encephalopathy; pure extracts of medicinal plants and herbs for the treatment of neurological diseases and conditions such as epilepsy and paediatric epilepsy, oncology, psychiatric disorders such as mood disorders and schizophrenia, type II diabetes, inflammation, cancer pain, multiple sclerosis spasticity and neonatal hypoxic-ischemic encephalopathy; foodstuffs for medicinal purposes, namely, plant oil for the treatment of neurological diseases and conditions such as epilepsy and paediatric epilepsy, oncology, psychiatric disorders such as mood disorders and schizophrenia, type II diabetes, inflammation, cancer pain, multiple sclerosis spasticity and neonatal hypoxic-ischemic encephalopathy; herb teas for the treatment of neurological diseases and conditions such as epilepsy and paediatric epilepsy, oncology, psychiatric disorders such as mood disorders and schizophrenia, type II diabetes, inflammation, cancer pain, multiple sclerosis spasticity and neonatal hypoxic-ischemic encephalopathy.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
31 - Produits agricoles; animaux vivants
Produits et services
Pharmaceutical, medical and veterinary preparations and
substances; pharmaceutical preparations and substances for
the treatment of epilepsy; pharmaceutical preparations and
substances for the treatment of pediatric epilepsy;
pharmaceutical preparations and substances for the treatment
of convulsions, seizures, Dravet syndrome, Lennox-Gastaut
syndrome, intractable childhood epilepsy with generalized
tonic-clonic seizures, generalized epilepsy with febrile
seizures plus, Doose syndrome and chromosome disorders;
herbs for medicinal purposes; medicinal herbs; medicinal
oils; medicinal infusions; medicinal infusions for the
treatment of epilepsy, convulsions and seizures; pure
extracts of medicinal plants and herbs; foodstuffs for
medicinal purposes; dietary supplements for humans and
animals; dietetic food and substances adapted for medical or
veterinary use; food for babies; herb teas for medicinal
purposes; medications for the treatment of multiple
sclerosis, pain associated with cancer, neuropathies and
rheumatoid arthritis; medicines for the treatment of
symptoms including pain, muscle spasticity and spasms,
bladder problems and sleep disorders; medications for the
treatment of conditions to which neuropathic pain is
associated, including multiple sclerosis, cancer, spinal
cord injury, physical trauma and peripheral neuropathy
resulting from diabetes; medicines for the treatment of
anorexia-cachexia, the result of cancer or AIDS, and nausea,
and secondary vomiting due to chemotherapy treatments. Agricultural and horticultural products; seeds; seedlings
for plant breeding; flowers; plants; plant residues (raw
materials); fresh herbs; foodstuffs and beverages for
animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
31 - Produits agricoles; animaux vivants
Produits et services
Pharmaceutical, medical and veterinary preparations and
substances; pharmaceutical preparations and substances for
the treatment of epilepsy; pharmaceutical preparations and
substances for the treatment of pediatric epilepsy;
pharmaceutical preparations and substances for the treatment
of convulsions, seizures, Dravet syndrome, Lennox-Gastaut
syndrome, intractable childhood epilepsy with generalized
tonic-clonic seizures, generalized epilepsy with febrile
seizures plus, Doose syndrome and chromosome disorders;
herbs for medicinal purposes; medicinal herbs; medicinal
oils; medicinal infusions; medicinal infusions for the
treatment of epilepsy, convulsions and seizures; pure
extracts of medicinal plants and herbs; foodstuffs for
medicinal purposes; dietary supplements for humans and
animals; dietetic food and substances adapted for medical or
veterinary use; food for babies; herb teas for medicinal
purposes; medications for the treatment of multiple
sclerosis, pain associated with cancer, neuropathies and
rheumatoid arthritis; medicines for the treatment of
symptoms including pain, muscle spasticity and spasms,
bladder problems and sleep disorders; medications for the
treatment of conditions to which neuropathic pain is
associated, including multiple sclerosis, cancer, spinal
cord injury, physical trauma and peripheral neuropathy
resulting from diabetes; medicines for the treatment of
anorexia-cachexia, the result of cancer or AIDS, and nausea,
and secondary vomiting due to chemotherapy treatments. Agricultural and horticultural products; seeds; seedlings
for plant breeding; flowers; plants; plant residues (raw
materials); fresh herbs; foodstuffs and beverages for
animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
31 - Produits agricoles; animaux vivants
Produits et services
Pharmaceutical, medical and veterinary preparations and
substances for animals; pharmaceutical medical and
veterinary preparations for animals with cannabinoids as
active ingredient; pharmaceutical preparations for animal
skincare; pharmaceutical and veterinary preparations and
substances for the treatment of epilepsy in animals;
pharmaceutical and veterinary preparations and substances
for the treatment of convulsions and seizures in animals;
medications for animals for the treatment of multiple
sclerosis, pain associated with cancer, neuropathies and
rheumatoid arthritis; medicines for animals for the
treatment of symptoms including pain, muscle spasticity and
spasms, bladder problems and sleep disorders; medications
for animals for the treatment of conditions to which
neuropathic pain is associated, including multiple
sclerosis, cancer, spinal cord injury, physical trauma and
peripheral neuropathy resulting from diabetes; herbs for
animals for medicinal purposes; medicinal herbs for animals;
medicinal oils for animals; medicinal infusions for animals;
medicinal infusions for animals for the treatment of
epilepsy, convulsions and seizures; pure extracts of
medicinal plants and herbs for animals; foodstuffs for
medicinal purposes for animals and pets; medicated animal
feed; medicated additives for animal feeds; dietary
supplements for animals; dietetic food and substances for
animals adapted for medical or veterinary use; herb teas for
animals for medicinal purposes. Agricultural and horticultural products; seeds; seedlings
for plant breeding; flowers; plants; plant residues (raw
materials); fresh herbs; foodstuffs and beverages for
animals; food for young animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
31 - Produits agricoles; animaux vivants
Produits et services
Pharmaceutical, medical and veterinary preparations and
substances; pharmaceutical medical and veterinary
preparations with cannabinoids as active ingredient;
pharmaceutical preparations for animal skincare;
pharmaceutical and veterinary preparations and substances
for the treatment of epilepsy; pharmaceutical and veterinary
preparations and substances for the treatment of convulsions
and seizures; medications for the treatment of multiple
sclerosis, pain associated with cancer, neuropathies and
rheumatoid arthritis; medicines for the treatment of
symptoms including pain, muscle spasticity and spasms,
bladder problems and sleep disorders; medications for the
treatment of conditions to which neuropathic pain is
associated, including multiple sclerosis, cancer, spinal
cord injury, physical trauma and peripheral neuropathy
resulting from diabetes; herbs for medicinal purposes;
medicinal herbs; medicinal oils; medicinal infusions;
medicinal infusions for the treatment of epilepsy,
convulsions and seizures; pure extracts of medicinal plants
and herbs; foodstuffs for medicinal purposes; medicated
animal feed; medicated additives for animal feeds; dietary
supplements for humans and animals; dietetic food and
substances adapted for medical or veterinary use; food for
babies or medicated food for young animals; herb teas for
medicinal purposes. Agricultural and horticultural products; seeds; seedlings
for plant breeding; flowers; plants; plant residues (raw
materials); fresh herbs; foodstuffs and beverages for
animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
31 - Produits agricoles; animaux vivants
Produits et services
Pharmaceutical, medical and veterinary preparations and
substances; pharmaceutical preparations and substances for
the treatment of epilepsy; pharmaceutical preparations and
substances for the treatment of pediatric epilepsy;
pharmaceutical preparations and substances for the treatment
of convulsions, seizures, Dravet syndrome, Lennox-Gastaut
syndrome, intractable childhood epilepsy with generalized
tonic-clonic seizures, generalized epilepsy with febrile
seizures plus, Doose syndrome and chromosome disorders;
herbs for medicinal purposes; medicinal herbs; medicinal
oils; medicinal infusions; medicinal infusions for the
treatment of epilepsy, convulsions and seizures; pure
extracts of medicinal plants and herbs; foodstuffs for
medicinal purposes; dietary supplements for humans and
animals; dietetic food and substances adapted for medical or
veterinary use; food for babies; herb teas for medicinal
purposes; medications for the treatment of multiple
sclerosis, pain associated with cancer, neuropathies and
rheumatoid arthritis; medicines for the treatment of
symptoms including pain, muscle spasticity and spasms,
bladder problems and sleep disorders; medications for the
treatment of conditions to which neuropathic pain is
associated, including multiple sclerosis, cancer, spinal
cord injury, physical trauma and peripheral neuropathy
resulting from diabetes; medicines for the treatment of
anorexia-cachexia, the result of cancer or AIDS, and nausea,
and secondary vomiting due to chemotherapy treatments;
pharmaceutical preparations with cannabinoids as active
ingredient. Agricultural and horticultural products; seeds; seedlings
for plant breeding; flowers; plants; plant residues (raw
materials); fresh herbs; foodstuffs and beverages for
animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
31 - Produits agricoles; animaux vivants
Produits et services
Pharmaceutical, medical and veterinary preparations and
substances; pharmaceutical preparations and substances for
the treatment of epilepsy; pharmaceutical preparations and
substances for the treatment of pediatric epilepsy;
pharmaceutical preparations and substances for the treatment
of convulsions, seizures, Dravet syndrome, Lennox-Gastaut
syndrome, intractable childhood epilepsy with generalized
tonic-clonic seizures, generalized epilepsy with febrile
seizures plus, Doose syndrome and chromosome disorders;
herbs for medicinal purposes; medicinal herbs; medicinal
oils; medicinal infusions; medicinal infusions for the
treatment of epilepsy, convulsions and seizures; pure
extracts of medicinal plants and herbs; foodstuffs for
medicinal purposes; dietary supplements for humans and
animals; dietetic food and substances adapted for medical or
veterinary use; food for babies; herb teas for medicinal
purposes; medications for the treatment of multiple
sclerosis, pain associated with cancer, neuropathies and
rheumatoid arthritis; medicines for the treatment of
symptoms including pain, muscle spasticity and spasms,
bladder problems and sleep disorders; medications for the
treatment of conditions to which neuropathic pain is
associated, including multiple sclerosis, cancer, spinal
cord injury, physical trauma and peripheral neuropathy
resulting from diabetes; medicines for the treatment of
anorexia-cachexia, the result of cancer or AIDS, and nausea,
and secondary vomiting due to chemotherapy treatments;
pharmaceutical preparations with cannabinoids as active
ingredient. Agricultural and horticultural products; seeds; seedlings
for plant breeding; flowers; plants; plant residues (raw
materials); fresh herbs; foodstuffs and beverages for
animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
31 - Produits agricoles; animaux vivants
Produits et services
Pharmaceutical, medical and veterinary preparations and
substances; pharmaceutical preparations and substances for
the treatment of epilepsy; pharmaceutical preparations and
substances for the treatment of pediatric epilepsy;
pharmaceutical preparations and substances for the treatment
of convulsions, seizures, Dravet syndrome, Lennox-Gastaut
syndrome, intractable childhood epilepsy with generalized
tonic-clonic seizures, generalized epilepsy with febrile
seizures plus, Doose syndrome and chromosome disorders;
herbs for medicinal purposes; medicinal herbs; medicinal
oils; medicinal infusions; medicinal infusions for the
treatment of epilepsy, convulsions and seizures; pure
extracts of medicinal plants and herbs; foodstuffs for
medicinal purposes; dietary supplements for humans and
animals; dietetic food and substances adapted for medical or
veterinary use; food for babies; herb teas for medicinal
purposes; medications for the treatment of multiple
sclerosis, pain associated with cancer, neuropathies and
rheumatoid arthritis; medicines for the treatment of
symptoms including pain, muscle spasticity and spasms,
bladder problems and sleep disorders; medications for the
treatment of conditions to which neuropathic pain is
associated, including multiple sclerosis, cancer, spinal
cord injury, physical trauma and peripheral neuropathy
resulting from diabetes; medicines for the treatment of
anorexia-cachexia, the result of cancer or AIDS, and nausea,
and secondary vomiting due to chemotherapy treatments;
pharmaceutical preparations with cannabinoids as active
ingredient. Agricultural and horticultural products; seeds; seedlings
for plant breeding; flowers; plants; plant residues (raw
materials); fresh herbs; foodstuffs and beverages for
animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and medical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols, for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical and medical preparations with cannabinoids as active ingredient, namely, a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical preparations and substances for the treatment of epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical preparations and substances for the treatment of convulsions and seizures associated with epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical and medical preparations for the treatment of symptoms associated with epilepsy including pain, muscle spasticity and spasms, bladder problems and sleep disorders associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; medicinal oils in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; medicinal infusions in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of epilepsy, convulsions and seizures associated with Dravet Syndrome and Lennox-Gestaut Syndrome
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and medical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols, for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical and medical preparations with cannabinoids as active ingredient, namely, a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical preparations and substances for the treatment of epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical preparations and substances for the treatment of convulsions and seizures associated with epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical and medical preparations for the treatment of symptoms associated with epilepsy including pain, muscle spasticity and spasms, bladder problems and sleep disorders associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; medicinal oils in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; medicinal infusions in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of epilepsy, convulsions and seizures associated with Dravet Syndrome and Lennox-Gestaut Syndrome
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and medical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols, for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical and medical preparations with cannabinoids as active ingredient, namely, a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical preparations and substances for the treatment of epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical preparations and substances for the treatment of convulsions and seizures associated with epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical and medical preparations for the treatment of symptoms associated with epilepsy including pain, muscle spasticity and spasms, bladder problems and sleep disorders associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; medicinal oils in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; medicinal infusions in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of epilepsy, convulsions and seizures associated with Dravet Syndrome and Lennox-Gestaut Syndrome
22.
USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATORY SKIN DISEASES
The present invention relates to the use of one or more cannabinoids in the treatment of an inflammatory skin disease. Preferably the one or more cannabinoids are taken from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigervarin (CBGV) and tetrahydrocannabivarin (THCV). The inflammatory skin disease may be caused by one or more of the following: microbial infection-induced dermatitis; solar dermatitis; atopic dermatitis; and allergic contact dermatitis.
A61K 31/047 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates ayant plusieurs groupes hydroxyle, p. ex. sorbitol
A61K 31/191 - Acides acycliques ayant plusieurs groupes hydroxyle, p. ex. acide gluconique
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
This invention relates to the use of CBD to treat mental disorders. For example it can be used as an adjunct therapy to treat positive symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat both positive and negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat anhedonia / asociality in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat avolition / apathy in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat disturbance of attention in mental disorders such as schizophrenia and related disorders; or as a monotherapy or as an adjunct therapy to treat one or more distinct sub-domains of negative symptoms selected from: i) avolition/ apathy; ii) anhedonia / asociality and iii) disturbance of attention; or as an adjunct therapy to treat cognitive symptoms, particularly working memory, motor speed and executive function in mental disorders such as schizophrenia and related disorders. There may additionally be provided compositions comprising CBD in combination with one or more antipsychotics such as olanzapine and quetiapine. In particular the invention relates to the treatment of schizophrenia or related psychotic disorders, more particularly still those which are considered to be treatment resistant.
The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy. In one embodiment the CBDA is used in the treatment of generalised seizures, preferably tonic-clonic seizures. Preferably the CBDA used is in the form of a botanical drug substance in which the CBDA content is greater than 60%, and most preferably, it is a highly purified extract of cannabis such that the CBDA is present at greater than 95%, through 96% and 97% to most preferably, greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoids tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA) have been substantially removed. Alternatively, the CBDA may be synthetically produced.
The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/353 - 3,4-Dihydrobenzopyranes, p. ex. chromane, catéchine
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of of nocturnal snoring. In particular the CBD appears particularly effective in treating nocturnal snoring in children and young adults with epilepsy The disclosure further relates to the use of CBD in5 combination with one or more anti-epileptic drugs (AEDs).
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
The present invention relates to the use of cannabinoids in the treatment of degenerative skeletal muscle disease. In particular the degenerative skeletal muscle disease is Duchenne muscular dystrophy (DMD). Preferably the cannabinoids are one or more of: Cannabidiol (CBD); Cannabidivarin (CBDV); and Tetrahydrocannabivarin (THCV).
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
The present disclosure relatesto the use of cannabidiol (CBD) for the treatment of seizures associated with Aicardi Syndrome. In one embodiment the seizures associated with Aicardi Syndrome are convulsive seizures; focal seizures with impairment or infantile spasm. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (NAFLD), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatotic livers results from the incorporation of plasma free fatty acids as well as de novo fat synthesis. The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) in the treatment of non-alcoholic fatty liver disease (NAFLD). Treatment of NAFLD involves lowering the triglyceride levels in a patient's blood stream.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
32.
ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER
The present invention relates to an active pharmaceutical ingredient (API) which comprises or consists essentially of cannabidiol (CBD) and one other cannabinoid selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV) for use as a medicament, and more particularly, for use in the treatment of cancer. These combinations have shown themselves to be synergistic in treating one or more of: breast cancer; liver cancer; lung cancer; pancreatic cancer; melanoma; ovarian cancer; gastric cancer; renal cancer or bladder cancer. Two particularly favored API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiolic (CBD) and tetrahydrocannabivarin (THCV).
The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and / or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy. Preferably the cannabinoid metabolites are isolated from plants to produce a highly purified extract or can be reproduced synthetically.
The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of "treatment-resistant epilepsy" (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
A61K 31/27 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbamiques ou thiocarbamiques, p. ex. méprobamate, carbachol, néostigmine
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p. ex. piracétam, éthosuximide
A61K 31/4166 - 1,3-Diazoles ayant des groupes oxo liés directement à l'hétérocycle, p. ex. phénytoïne
A61K 31/423 - Oxazoles condensés avec des carbocycles
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
A61K 31/5513 - 1,4-Benzodiazépines, p. ex. diazépam
A61K 31/5517 - 1,4-Benzodiazépines, p. ex. diazépam condensées avec des cycles à cinq chaînons ayant l'azote comme hétéro-atome d'un cycle, p. ex. imidazobenzodiazépines, triazolam
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61P 25/10 - AntiépileptiquesAnticonvulsivants pour le traitement du petit-mal
The present disclosurerelates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering withetiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q;, Jeavons syndrome; Myoclonic Absence Epilepsy;Neuronal ceroid lipofuscinoses(NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
A61K 31/27 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbamiques ou thiocarbamiques, p. ex. méprobamate, carbachol, néostigmine
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p. ex. piracétam, éthosuximide
A61K 31/4166 - 1,3-Diazoles ayant des groupes oxo liés directement à l'hétérocycle, p. ex. phénytoïne
A61K 31/423 - Oxazoles condensés avec des carbocycles
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
A61K 31/5513 - 1,4-Benzodiazépines, p. ex. diazépam
A61K 31/5517 - 1,4-Benzodiazépines, p. ex. diazépam condensées avec des cycles à cinq chaînons ayant l'azote comme hétéro-atome d'un cycle, p. ex. imidazobenzodiazépines, triazolam
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61P 25/10 - AntiépileptiquesAnticonvulsivants pour le traitement du petit-mal
36.
THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA
The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
The present invention relates to the use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer. Preferably the phytocannabinoids used are either tetrahydrocannabinol (THC) and / or cannabidiol (CBD). Preferably the type of cancer to be treated is glioma.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations and substances;
pharmaceutical preparations and substances for the treatment
of epilepsy, paediatric epilepsy, oncology, psychiatric
disorders, type II diabetes, inflammation, cancer pain, MS
spasticity and neonatal hypoxic-ischemic encephalopathy;
herbs for medicinal purposes; medicinal herbs; medicinal
oils; medicinal infusions; pure extracts of medicinal plants
and herbs; foodstuffs for medicinal purposes; herb teas for
medicinal purposes.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations and substances;
pharmaceutical preparations and substances for the treatment
of epilepsy, paediatric epilepsy, oncology, psychiatric
disorders, type II diabetes, inflammation, cancer pain, MS
spasticity and neonatal hypoxic-ischemic encephalopathy;
herbs for medicinal purposes; medicinal herbs; medicinal
oils; medicinal infusions; pure extracts of medicinal plants
and herbs; foodstuffs for medicinal purposes; herb teas for
medicinal purposes.
40.
TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING
The present invention relates to the use of tetrahydrocannabivarin (THCV) in the treatment of nausea and vomiting. Preferably the THCV is isolated and / or purified from cannabis plant extracts. Preferably the nausea and / or vomiting is caused by the effects of a medication such as a chemotherapeutic agent.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 1/08 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des nausées, du mal des transports ou des vertigesAntiémétiques
41.
SYNERGISTIC THERAPIES OF CANNABIDIOL WITH HYPOTHERMIA FOR NEUROPROTECTION
The present invention relates to the combination of the phytocannabinoid cannabidiol with therapeutic hypothermia for use in the treatment of neuroprotection or astroprotection.
The present invention relates to the phytocannabinoid tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells. Preferably the pancreatic islet cells to be protected are beta cells. More preferably the protection of the pancreatic islet cells maintains insulin production at levels which are able to substantially control or improve control of blood glucose levels in a patient.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
43.
PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES
The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn's disease.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
44.
PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER
The present invention relates to phytocannabinoids for use in the treatment of a breast cancer. In a first embodiment the invention relates to an oral presentation of tetrahydrocannabinol (THC) for use in the treatment of aggressive breast cancer, characterised by overexpression of the Her2 gene. In a second embodiment the invention relates to the phytocannabinoid cannabidiol (CBD) for use in the treatment of aggressive breast cancer, characterised by overexpression of the Her2 gene. In a third embodiment the invention relates to the combination of the phytocannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use in the treatment of breast cancer or to treat, prevent or to reduce the risk of a cancer metastasising.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV)and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non- cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and / or cannabichromene (CBC).More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and / or CBD.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
The present invention relates to the use of phytocannabinoids in the treatment of cancer. More particularly it relates to the use of phytocannabinoids in the treatment of tumour cell invasion and cell migration or metastases. Cancers, where invasion and cell migration plays a key role in prognosis include brain tumours, more particularly gliomas, and most particularly Glioblastoma multiforme (GBM) and breast cancers. The phytocannabinoids tetrahydrocannabivarin (THCV) and cannabidivarin (CBDV) alone or in combination with each other and/ or other phytocannabinoids, particularly cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabigerol (CBG) or their respective acids are of particular use.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/353 - 3,4-Dihydrobenzopyranes, p. ex. chromane, catéchine
The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and / or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease.
A61K 31/185 - AcidesLeurs anhydrides, halogénures ou sels, p. ex. acides du soufre, acides imidiques, hydrazoniques ou hydroximiques
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
48.
CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN
The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and / or purified from cannabis plant extracts.
A61K 31/185 - AcidesLeurs anhydrides, halogénures ou sels, p. ex. acides du soufre, acides imidiques, hydrazoniques ou hydroximiques
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
49.
CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN
The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and / or purified from cannabis plant extracts.
A61K 31/185 - AcidesLeurs anhydrides, halogénures ou sels, p. ex. acides du soufre, acides imidiques, hydrazoniques ou hydroximiques
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
50.
USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY
The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels,for use in the treatment of epilepsy.The SAED is preferably one which modifies low-threshold or transient neuronal calcium currents,or reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p. ex. piracétam, éthosuximide
The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels,for use in the treatment of epilepsy.The SAED is preferably one which • modifies low-threshold or transient neuronal calcium currents,or • reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p. ex. piracétam, éthosuximide
This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
57.
USE OF TETRAHYDROCANNABIVARIN IN THE TREATMENT OF GENERALISED SEIZURES
Cannabis has been ascribed as both pro-convulsant and anti-convulsant and it remains to be determined if they can be used in the treatment of epilepsy. The present disclosure relates to the use of tetrahydrocannabivarin in the treatment of epilepsy and more particularly in the treatment of generalized seizures. In one embodiment it relates to tetrahydrocannabivarin (THCV) or a composition containing same for use in the treatment of generalised seizures or for use in the preparation of a medicament for treating generalised seizures .
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary products; hygienic and
sanitary products for medical use; dietetic substances
adapted for medical use, food for babies; plasters,
materials for dressings; material for stopping teeth and
dental wax; disinfectants; products for destroying vermin;
fungicides, herbicides.
59.
USE OF A COMBINATION OF DELTA-9-TETRAHYDROCANNBINOL AND CANNABIDIOL IN THE TREATMENT OF BRAIN CANCER
The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM).
The invention relates to the use of one or more cannabinoids, particularly THC and/ or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme(GBM).The non- cannabinoid chemotherapeutic agent may be a selective estrogen receptor modulator or an alkylating agent.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/4535 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p. ex. pizotifène
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine
The invention relates to the use of one or more cannabinoids, particularly THC and/ or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme(GBM).The non- cannabinoid chemotherapeutic agent may be a selective estrogen receptor modulator or an alkylating agent.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/4535 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p. ex. pizotifène
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM).
The present invention relates to plants producing, as their major cannabinoid cannabichromenic acid (CBCA) or its neutral (decarboxylated) form cannabichromene (CBC), hereafter jointly referred to as CBC(A). It additionally relates to: • A botanical material obtainable from said plants; • A botanical raw material (BRM), • An extract including a botanical drug substance (BDS) and a purified BDS; • A formulation comprising the BRM, BDS, purified BDS or other extract; • The use of the BRM, BDS, purified BDS or other extract in the manufacture of a medicament; • A method of deriving plants yielding a high proportion of the cannabinoid CBC (A) at the expense of other cannabinoids; • A method of cultivating plants such that they yield a high proportion of the cannabinoid CBC(A) at the expense of other cannabinoids; and • A method of extracting CBC(A) from said plants.
The present invention relates to the use of CBD alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in controlling cholesterol levels in a subject. It also relates to the use of THCV alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in increasing energy expenditure in a subject. Furthermore the CBD alone or in combination with another cannabinoid or the THCV alone or in combination with another cannabinoid are used as part of a regime to manage or treat type I or II diabetes, obesity, dyslipidaemia, related metabolic disorders and cardiovascular disease.
The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.
A61K 31/35 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/35 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle
The present invention relates to the use of cannabidiol for use in the prevention or treatment of transmissible neurodegenerative conditions. Preferably the neurodegenerative condition to be prevented or treated is prion disease.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
68.
NEW PHARMACEUTICAL FORMULATION COMPRISING CANNABIDIOL AND TETRAHYDROCANNABIDIVARIN
The present invention relates to a novel pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CB1 and/or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CB1 and/or CB2 receptor. Preferably both the inverse agonist of the CB1 and/or CB2 receptor and the neutral antagonist of the CB1 and/or CB2 receptor are cannabinoids. Preferably the cannabinoids are tetrahydrocannabidivarin (THCV) and cannabidiol (CBD).
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
The present invention relates to the use of a substantially pure tetrahydrocannabinol (THC) or a THC containing extract in which THC is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. A further embodiment of the invention relates to the use of a substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. Additionally the substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid are used in the manufacture of a medicament for use as an adjunct therapy in the treatment of an inflammatory bowel disease.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CBi and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
71.
A NOVEL REFERENCE PLANT, A METHOD FOR ITS PRODUCTION, EXTRACTS OBTAINED THEREFROM AND THEIR USE
The present invention relates to a novel reference plant, a method for producing a novel reference plant, extracts free of a medicinally active compound or group of compounds obtained therefrom and their use. More particularly, the novel reference plant is a plant derived from a comparator plant. In an exemplifying embodiment the medicinal compounds, which are 'knocked out', are one or more cannabinoids and the plant is a cannabis, Cannabis sativa, plant.
The present invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of diseases or conditions that are alleviated by blockade of one or more types of TRP channel. Preferably the subset of TRP channel that is blockaded is the TRPA channel. More preferably the TRPA channel is the TRPA1 channel. Preferably the diseases or conditions to be prevented or treated include: neuropathic pain, inflammation or vasoconstriction. Alternatively the TRP channel that is blockaded is the TRPM channel. More preferably the TRPM channel is the TRPM8 channel. Preferably the diseases or conditions to be prevented or treated are cancer. More preferably the cancers to be treated include: cancer of the prostate, cancer of the breast, cancer of the colon, cancer of the lung or cancer of the skin. Alternatively the TRP channel that is blockaded is the TRPV channel. More preferably the TRPV channel is the TRPV1 channel. Preferably the diseases or conditions to be prevented or treated include neuropathic pain, inflammation or vasoconstriction.
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydrocannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
74.
CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN
The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydrocannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
75.
USE OF PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIGEROL FOR THE TREATMENT OF DEPRESSION
The present invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in 0 the treatment of diseases and conditions benefiting from inverse agonism of the CB1 and / or the CB2 cannabinoid receptor. Preferably the cannabinoid is a cannabidiol (CBD) type compound or derivative thereof .
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
The invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration. In particular, the invention relates to use of one or more cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration, wherein the one or more cannabinoid-containing plant extracts comprise: i) a cannabinoid-containing fraction; and ii) a non-cannabinoid containing fraction.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
79.
A COMBINATION OF CANNABINOIDS FOR THE TREATMENT OF PERIPHERAL NEUROPHATIC PAIN
The present invention relates to the use of a combination of cannabinoids in the treatment of neuropathic pain, in particular peripheral neuropathic pain. A combination of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may be used, wherein the ratio of CBD:THC by weight is between 10:1 and 1:10.
A61K 31/047 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates ayant plusieurs groupes hydroxyle, p. ex. sorbitol
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
80.
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
The invention relates to the use of a combination of cannabinoids for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Preferably the combination of cannabinoids are cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/35 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle
82.
USE OF TETRAHYDROCANNABIVARIN (THCV) AS NEUTRAL ANTAGONIST OF THE CB1 CANNABINOID RECEPTOR
The invention relates to the use of one or more cannabinolds in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type II diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.
The invention relates to the use of a cannabis plant extract or a cannabinoid as a pharmaceutically active agent in the inhibition of tumour cell migration.
